23 July 2026
Medicine safety is in focus as the iDexis court case raises questions about compounding, regulation and patient monitoring.
13 July 2026
Telehealth GLP-1 prescribing practices may expose patients to unsafe care, weak medical checks and compounded weight-loss drugs.
23 June 2026
iDexis semaglutide ban stops the pharmacy group from selling compounded weight-loss medicines while SAHPRA and the SAPC investigate.
2 June 2026
The Semaglutide Compounding Dispute intensifies as Novo Nordisk takes iDexis to court over illegal manufacturing of weight-loss injections.